Company / Revenue per Share
Apellis Pharmaceuticals, Inc. Revenue per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$8.06
FY2025
5-year range
$0.77 / $8.06
FY2021-FY2025
Trend
+23.4%
vs FY2024
Sector context
#52 of 154
Health Care
What the data says
At $8.06, Apellis Pharmaceuticals, Inc.'s revenue per share ranks #52 of 154 in the Health Care sector. Revenue per Share has increased for 3 consecutive years, from $0.77 in FY2022 to $8.06 in FY2025.
Based on SEC 10-K filings.
8.06 in FY2025 with a 5-year CAGR of +15.5%.
Improved from $3.58 to $8.06 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +118.5%
- 5-Year CAGR
- +15.5%
- 10-Year CAGR
- -
Sector benchmark
#52 of 154 in Health CareTop 34% of 154This company $8.06 Sector average $15.09
▼
-46.6% below sector average
Key checks
Key Insights
- Apellis Pharmaceuticals, Inc.'s revenue per share has grown for 3 consecutive years.
- In FY2025, revenue per share increased 23.4% year-over-year.
- Ranks #52 out of 154 companies in the Health Care sector.
- Lowest revenue per share in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.06 | +23.4% |
| FY2024 | $6.54 | +82.5% |
| FY2023 | $3.58 | +362.9% |
| FY2022 | $0.77 | -11.5% |
| FY2021 | $0.87 | -77.7% |
| FY2020 | $3.92 | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026